​Litteratur til Body Image Disorders

  • Bijl R.V., Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 1998;33(12):587-595
  • Bushnell J.A., Wells JE, Hornblow AR, Oakley-Browne MA, Joyce P. Prevalence of three bulimia syndromes in the general population. Psychol Med. 1990;20(3):671-680
  • Garfinkel P.E., Lin E, Goering P, Spegg C, Goldbloom D, Kennedy S, Kaplan AS, Woodside DB. Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? evidence from a Canadian community
  • Garfinkel P.E., Lin E, Goering P, Spegg C, Goldbloom DS, Kennedy S, Kaplan AS, Woodside DB. Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups. Am J Psychiatry. 1995;152(7):1052-1058
  • sample. Br J Psychiatry. 1996;168(4):500-506
  • Hudson J.I., Hiripi E, Pope HG Jr, Kessler RC The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007 Feb 1; 61(3):348-58.
  • Kendler K.S., MacLean C, Neale M, Kessler R, Heath A, Eaves L. The genetic epidemiology of bulimia nervosa. Am J Psychiatry. 1991;148(12):1627-1637
  • Preti A., Girolamo G, Vilagut G, Alonso J, Graaf R, Bruffaerts R, Demyttenaere K, Pinto-Meza A, Haro JM, Morosini P.ESEMeD-WMH Investigators. The epidemiology of eating disorders in six European countries: results of the ESEMeD-WMH project. J Psychiatr Res. 2009;43(14):1125-1132
  • Smink F.R., van Hoeken D, Hoek HW.Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep. 2012 Aug;14(4):406-14. doi: 10.1007/s11920-012-0282-y.
  • Strother E., Lemberg R, Stanford SC, Turbeville D. Eating disorders in men: undergdiagnosed, undertreated, and misunderstood. Eating disorders. 2012;20:346–355.
  • Walters E.E., Kendler KS. Anorexia nervosa and anorexic-like syndromes in a population-based female twin sample. Am J Psychiatry. 1995;152(1):64-71
  • Wooldridge T. & Lytle P.P. “An overview of anorexia nervosa in males”. Eat Disord. 2012; 20(5):368-78.

​Litteratur til Body Dysmorphic Disorder

  • Chung B. Muscle dysmorphia: a critical review of the proposed criteria. Perspect Biol Med. 2001;44:565–574
  • Cohane G.H. & Pope H.G., Jr. Body image in boys: a review of the literature. Int J Eat Disord. 2001;29:373–379.
  • Dawes J. & Mankin T. Muscle dysmorphia. Strength Cond J. 2004;26:24–25.
  • Grant J.E., Kim SW, Crow SJ. Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. J Clin Psychiatry. 2001;62(7):517–522.
  • Ishigooka J, Iwao M, Suzuki M, Fukuyama Y, Murasaki M, Miura S. Demographic features of patients seeking cosmetic surgery. Psychiatry Clin Neurosci. 1998;52(3):283–287.
  • Leone J.E., Sedory EJ, Gray KA. Recognition and treatment of muscle dysmorphia and related body image disorders. J Athl Train. 2005;40(4):352–359.​
  • Phillips K.A., McElroy SL, Keck PE, Jr, Pope HG, Jr, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 1993;150(2):302–308.
  • Phillips K.A., Nierenberg AA, Brendel G, Fava M. Prevalence and clinical features of body dysmorphic disorder in atypical major depression. J Nerv Ment Dis. 1996;184(2):125–129.
  • Phillips K.A. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. Rev ed. New York: Oxford University Press; 2005.
  • Phillips KA, Dufresne RG, Jr, Wilkel CS, Vittorio CC. Rate of body dysmorphic disorder in dermatology patients. J Am Acad Dermatol. 2000;42(3):436–441.
  • Pope H.G. Jr, Phillips KA, Olivardia R. The Adonis Complex: The Secret Crisis of Male Body Obsession. New York, NY: The Free Press; 2000.​
  • Sarwer DB, Wadden TA, Pertschuk MJ, Whitaker LA. Body image dissatisfaction and body dysmorphic disorder in 100 cosmetic surgery patients. Plast Reconstr Surg. 1998;101(6):1644–1649.
  • Tiggemann M. Body-size dissatisfaction: individual differences in age and gender, and relationship with self-esteem. Pers Individ Dif. 1992;13:39–43.
  • Uzun O, Basoglu C, Akar A, et al. Body dysmorphic disorder in patients with acne. Compr Psychiatry. 2003;44(5):415–419.
  • Zimmerman M. & Mattia J.I. Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates. Compr Psychiatry. 1998;39(5):265–270.​

​Litteratur til Tourette syndrom

  • Albin R.L., R.A. Koeppe, K. Wernette, W. Zhuang, T. Nichols, M.R. Kilbourn, K.A. FreyStriatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome”. Neurology, 72 (2009), pp. 1390-1396.
  • Coffey B.J., Biederman J, Geller D, Frazier J, Spencer T, Doyle R, Gianini L, Small A, Frisone DF, Magovcevic M, Stein N, Faraone SV Reexamining Tic persistence and Tic-associated impairment in Tourette's Disorder: findings from a naturalistic follow-up study.J Nerv Ment Dis. 2004 Nov; 192(11):776-80.
  • Freeman R.D. “Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome”. European Child & Adolescent Psychiatry, July 2007, Volume 16, Supplement 1, pp 15–23.​
  • George M.S., M.M. Robertson, D.C. Costa, P.J. Ell, M.R. Trimble, L. Pilowsky, N.P. VerhoeffDopamine receptor availability in Tourette's syndrome”. Psychiatry Res., 55 (1994), pp. 193-203
  • Gilbert D.L., B.T. Christian, M.J. Gelfand, B. Shi, J. Mantil, F.R. Sallee “Altered mesolimbocortical and thalamic dopamine in Tourette syndrome”. Neurology, 67 (2006), pp. 1695-1697
  • Gilbert D.L., Ridel K.R., Sallee FR, et al. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology. 2006;31:442–9.
  • Horwath E. & Weissman M.M.; 2000, Khalifa N. & Knorring A-L. Prevalence of tic disorders and Tourette syndrome in a Swedish school population. Dev Med Child Neurol. 2003;45(5):315–319.
  • Liu H., Dong F, Meng Z, Zhang B, Tan J, Wang Y. Dong F, Meng Z, Zhang B, Tan J, Wang Y. Evaluation of Tourette’s syndrome by (99m)Tc-TRODAT-1 SPECT/CT imaging. Ann. Nucl. Med. 24, 515–521 (2010).
  • McMahon W.M., Carter AS, Fredine N, Pauls DL.”Children at familial risk for Tourette's disorder: Child and parent diagnoses. Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):105-11.
  • Meyer P., N.I. Bohnen, S. Minoshima, R.A. Koeppe, K. Wernette, M.R. Kilbourn, D.E. Kuhl, K.A. Frey, R.L. Albin Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome”. Neurology, 53 (1999), pp. 371-374
  • Mink J. W. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Adv. Neurol. 99, 89–98 (2006).
  • Nee L.E., Cane E.D., Polinsky R.J. Eldridge R. & Ebert M.H. “Gilles de la tourette syndrome: Clinical and family study of 50 cases”. Volume 7, Issue 1, Pages 41–49, January 1980.
  • Oluwabusi O.O., Parke S. & Ambrosini “Tourette syndrome associated with attention deficit hyperactivity disorder: The impact of tics and psychopharmacological treatment options”. World J Clin Pediatr. 2016 Feb 8; 5(1): 128–135.
  • Riahi F., Izadi-Mazidi M. & Abdi S.M. “Prevalence of Comorbid Psychiatric Disorders in Children and Adolescents With Attention Deficit Hyperactivity Disorder”. Jentashapir J Health Res. 2015 August; 6(4): e25662.
  • Robertson M.M., Eapen V, Cavanna AE The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009 Dec; 67(6):475-83.
  • Robertson M.M., M.D., D.Sc. (Med.), Andrea E. Cavanna, M.B.Ch.B., M.D., Ph.D., Valsamma Eapen, M.B.B.S., Ph.D., F.R.C.Psych. “Gilles de la Tourette Syndrome and Disruptive Behavior Disorders: Prevalence, Associations, and Explanation of the Relationships”. J Neuropsychiatry Clin Neurosci 27:1, Winter 2015.
  • Robertson M.M. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. Lancet Psychiatry. 2015;2(1):68–87.
  • Robertson M.M., M.D., D.Sc. (Med.), Andrea E. Cavanna, M.B.Ch.B., M.D., Ph.D., Valsamma Eapen, M.B.B.S., Ph.D., F.R.C.Psych. “Gilles de la Tourette Syndrome and Disruptive Behavior Disorders: Prevalence, Associations, and Explanation of the Relationships”. J Neuropsychiatry Clin Neurosci 27:1, Winter 2015.
  • Robertson M.M. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. Lancet Psychiatry. 2015;2(1):68–87.
  • Scharf J.M., Miller LL, Gauvin CA, Alabiso J, Mathews CA, Ben-Shlomo Y. Population prevalence of Tourette syndrome: A systematic review and meta-analysis: Meta-Analysis of TS Prevalence. Mov Disord. 2015 Feb;30(2):221–8.
  • Schlander M., Schwarz O, Rothenberger A, Roessner V “Tic disorders: administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample. Eur Psychiatry. 2011 Sep; 26(6):370-4.
  • Segura, B. & Strafella, A. P. Functional imaging of dopaminergic neurotransmission in Tourette syndrome. Int. Rev. Neurobiol. 112, 73–93 (2013).
  • Simpson H.A., Jung L. & Murphy T.K. ”Update on Attention-Deficit/Hyperactivity Disorder and Tic Disorders: A Review of the Current Literature”. Current Psychiatry Reports volume 13, Article number: 351 (2011)
  • Singer H.S., S. Szymanski, J. Giuliano, F. Yokoi, A.S. Dogan, J.R. Brasic, Y. Zhou, A.A. Grace, D.F. WongElevated intrasynaptic dopamine release in Tourette's syndrome measured by PET Am. J. Psychiatry, 159 (2002), pp. 1329-133.
  • Sukhodolsky D.G., Scahill L., Zhang H., Peterson B.S., King R.A., Lombroso P.J., Katsovich L., Findley D. & Leckman J.F. “Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment”. J Am Acad Child Adolesc Psychiatry. 2003 Jan;42(1):98-105.
  • Tremblay L., Worbe Y., Thobois S., Sgambato-Faure V. & Feger, J. Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders. Mov. Disord. 30, 1155–1170 (2015).
  • Turjanski N., G.V. Sawle, E.D. Playford, R. Weeks, A.A. Lammerstma, A.J. Lees, D.J. BrooksPET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome”. J. Neurol. Neurosurg. Psychiatry, 57 (1994), pp. 688-692
  • Wong D.F., H.S. Singer, J. Brandt, E. Shaya, C. Chen, J. Brown, A.W. Kimball, A. Gjedde, R.F. Dannals, H.T. Ravert, P.D. Wilson, H.N. Wagner Jr. “D2-like dopamine receptor density in Tourette syndrome measured by PET”. J. Nucl. Med., 38 (1997), pp. 1243-1247
  • Wong D.F., J.R. Brasic, H.S. Singer, D.J. Schretlen, H. Kuwabara, Y. Zhou, A. Nandi, M.A. Maris, M. Alexander, W. Ye, O. Rousset, A. Kumar, Z. Szabo, A. Gjedde, A.A. Grace Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET”. Neuropsychopharmacology, 33 (2008), pp. 1239-1251​

​Litteratur til ADHD/ADD

  • Atladottir H.O., Parner ET, Schendel D, Dalsgaard S, Thomsen PH, Thorsen P. Time trends in reported diagnoses of childhood neuropsychiatric disorders: A danish cohort study. Arch Pediatr Adolesc Med. 2007;161(2):193-198.
  • Atladottir H.O., Gyllenberg D, Langridge A, et al. The increasing prevalence of reported diagnoses of childhood psychiatric disorders: A descriptive multinational comparison. Eur Child Adolesc Psychiatry. 2015;24(2):173-183.
  • Bergman S., Joseph O’Neill, Scott Fears, George Bartzokis, and Edythe D. London “Abuse of Amphetamines and Structural Abnormalities in BrainAnn N Y Acad Sci. 2008 Oct; 1141: 195–220.
  • Black J.E., Kodish I.M., Grossman A.W., Klintsova A.Y., Orlovskaya D., Vostrikov V. et al (2004). Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161: 742–744.
  • Broadbelt K., Byne W., Jones L.B. (2002). Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res 58: 75–81.
  • Buxton N. & McConachie N.S. Amphetamine abuse and intracranial haemorrhage. J R Soc Med 2000;93472- 477.
  • Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res. 2007 Apr;11(3-4):183-202.
  • Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012 Jan 1;120(1-3):35-40. doi: 10.1016/j.drugalcdep.2011.06.013. Epub 2011 Jul 26.
  • Castle L., Aubert R.E., Verbrugge R.R., Khalid M., Epstein R.S. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335-342.
  • Chien I.C., Lin CH, Chou YJ, Chou P. Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in taiwan, 1996-2005: A national populationbased study. Soc Psychiatry Psychiatr Epidemiol. 2012;47(12):1885-1890.
  • Cordonnier C. & Van Der Flier W.M. “Brain microbleeds and Alzheimer's disease: innocent observation or key player?” 2011 Feb;134(Pt 2):335-44.
  • Cruickshank C.C. & Dyer K.R. “A review of the clinical pharmacology of methamphetamine”. Addiction, Volume 104, Issue 7, Pages 1085–1099, July 2009.
  • Curtin K., Annette E., Fleckenstein C.G., Reid J., Robison D.E., Michael J. Crookstond, Ken R.Smith, Glen R.Hanson “Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment”. Drug and Alcohol Dependence, Volume 146 react-text: 71 , /react-text react-text: 72 1 January 2015 /react-text react-text: 73 , Pages 30-38.
  • Curtin K., A.E. Fleckenstein, B.R. Keeshin, D.A. Yurgelun-Todd, P.F. Renshaw, K.R. Smith, G.R. Hanson. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology. 2018 Dec; 43(13): 2548-2555. doi: 10.1038/s41386-018-0207-5. Epub 2018 Sep 12.
  • Curtin K., Fleckenstein, AE, Keeshin, BR, Yurgelun-Todd, DA, Renshaw, PF, Smith, KR, Hanson, GR. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology. 2018;43(13):2548–2555.
  • Davidovitch M., Gideon Koren, Naama Fund, Maayan Shrem, and Avi Porath“Challenges in defining the rates of ADHD diagnosis and treatment: trends over the last decade”. BMC Pediatr. 2017; 17: 218.
  • Dalsgaard S., Nielsen HS, Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A danish register-based study. J Child Adolesc Psychopharmacol. 2013;23(7):432-439
  • Delaney P. & Estes M. “Intracranial hemorrhage with amphetamine abuse”. Neurology 1980;30.1125- 1128.
  • Furman L. What is attention-deficit hyperactivity disorder (ADHD)? J Child Neurol. 2005 Dec;20(12):994-1002.
  • Garey L.J., Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM et al (1998). Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 65: 446–453.
  • Glantz A.L. & Lewis D.D. ”Decreased dendrittc spine density on prefrontal cortical neurons in schizophernia”. Arch Gen Psychiatry 57; 65-73, 2000.
  • Granado N., Sara Ares-Santos, 1 , 2 and Rosario Moratalla “Methamphetamine and Parkinson's Disease Parkinsons Dis. 2013; 2013: 308052.
  • Hodgkins P., Setyawan J, Mitra D, Davis K, Quintero J, Fridman M, Shaw M, Harpin V “Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns”. Eur J Pediatr. 2013 Jul; 172(7):895-906.
  • Kalus P., Muller TJ, Zuschratter W, Senitz D (2000). The dendritic architecture of prefrontal pyramidal neurons in schizophrenia patients. Neuroreport 11: 3621–3625.
  • Langager S., Children and youth in behavioural and emotional difficulties, skyrocketing diagnosis and inclusion/exclusion processes in school tendencies in Denmark”. Emotional and Behavioural Difficulties, Volume 19, 2014.
  • Lappin J.M., Darke S. & Farrell M. 2Stroke and methamphetamine use in young adults: a review”. J Neurol Neurosurg Psychiatry, 2017 Dec;88(12):1079-1091.
  • Lichtenfeld P.J., Rubin D.B., Feldman R.S. “Subarachnoid hemorrhage precipitated by cocaine snorting”. Arch Neurol 1984;41223- 224.
  • McCarthy S., Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr. 2012;12:78-2431-12-78.
  • Petitti D.B., Sidney S, Quesenberry C, Bernstein A. “Stroke and cocaine or amphetamine use. Epidemiology. 1998 Nov;9(6):596-600.
  • Rapoport J.L., Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ. ”Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science. 1978 Feb 3;199(4328):560-3.
  • Rapoport J.L. & Inoff-Germain G. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002. J Atten Disord. 2002; 6 Suppl 1():S57-60.
  • Selemon L.D., Begović A, Goldman-Rakic PS, Castner SA “Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate”. Neuropsychopharmacology. 2007 Apr; 32(4):919-31.
  • Westover A.N., Susan McBride, RN, PhD; Robert W. Haley, MD “Stroke in Young Adults Who Abuse Amphetamines or Cocaine. A Population-Based Study of Hospitalized Patients”. Arch Gen Psychiatry. 2007;64(4):495-502.

​Litteratur til helbredsangst

  • Barsky AJ, Ahern DK. Cognitive Behavior Therapy for Hypochondriasis: A Randomized Controlled Trial. JAMA. 2004;291(12):1464–1470​
  • Bouman, Theo & Visser, Sako. (1998). Cognitive and Behavioural Treatment of Hypochondriasis. Psychotherapy and psychosomatics. 67. 214-21.
  • ​Salkovskis, Warwick, Deale Cognitive Behavioral Model Of Health Anxiety Cognitive Behavioral Model Of Health Anxiety (2003)

Har du spørgsmål?

Udfyld nedenstående kontaktformular, hvorefter vi kontakter dig.

Skriv meget gerne tidspunkt for, hvornår du vil kontaktes.​

Nogle felter er ikke udfyldt korrekt

Besøg klinikken

​​Ny Vestergårdsvej 5b, 3500 Værløse

CVR-nummer: 26989264

Klik her for rutevejledning


Mandag - fredag

9.00 - 13.00

Vores søde og rare sekretær Maida kan træffes mellem 9.00-13.00 mandag til fredag på telefon: 70 26 06 76


​​Telefon: 70 26 06 76


Har du spørgsmål?

Udfyld nedenstående kontaktformular, hvorefter vi kontakter dig. 

Skriv meget gerne tidspunkt for, hvornår du vil kontaktes.​

Nogle felter er ikke udfyldt korrekt